US FDA News: FDA approves new treatment for moderately to severely active ulcerative colitis

FDA today expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely active ulcerative colitis.
Read more: FDA approves new treatment for moderately to severely active ulcerative colitis